- Home
- ROIV vs JBHT Comparison
ROIV vs JBHT Comparison
Compare ROIV & JBHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | JBHT |
|---|---|---|
| Founded | 2014 | 1961 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trucking Freight/Courier Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 21.2B |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ROIV | JBHT |
|---|---|---|
| Price | $28.02 | $249.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 20 |
| Target Price | $28.94 | ★ $220.80 |
| AVG Volume (30 Days) | ★ 4.4M | 811.8K |
| Earning Date | 05-28-2026 | 04-15-2026 |
| Dividend Yield | N/A | ★ 0.73% |
| EPS Growth | N/A | ★ 10.07 |
| EPS | N/A | ★ 1.49 |
| Revenue | $29,053,000.00 | ★ $7,189,568,000.00 |
| Revenue This Year | N/A | $5.76 |
| Revenue Next Year | $744.61 | $6.62 |
| P/E Ratio | ★ N/A | $168.49 |
| Revenue Growth | N/A | ★ 9.67 |
| 52 Week Low | $10.58 | $130.13 |
| 52 Week High | $30.33 | $256.18 |
Technical Indicators
Market Signals| Indicator | ROIV | JBHT |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 63.47 |
| Support Level | $27.00 | $195.69 |
| Resistance Level | $30.26 | $256.18 |
| Average True Range (ATR) | 0.90 | 7.59 |
| MACD | -0.14 | 0.28 |
| Stochastic Oscillator | 31.41 | 78.56 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About JBHT J.B. Hunt Transport Services Inc.
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (48% of sales), dedicated trucking services that provide customer-specific fleet needs (27%), for-hire truckload (6%), heavy goods final-mile delivery (7%), and asset-light truck brokerage (12%).